A photo of Alexander Vinks.

Director, Division of Clinical Pharmacology

Scientific Director, Pharmacy Research, Research in Patient Services

Professor, UC Department of PediatricsAdjunct Professor of Pharmacology



Biography & Affiliation


I have been a researcher for more than 37 years and began working at Cincinnati Children's in 2000. My research is in pharmacokinetic-pharmacodynamic (PK/PD) modeling and simulation, systems pharmacology, physiologically based pharmacokinetics (PBPK) and pharmacogenetics/genomics. I am also interested in applying population and simulation methods to inform pediatric clinical trial design and therapeutic drug management by implementing model-informed precision dosing strategies and clinical decision support tools.

I became interested in this research early in my career when I directed a therapeutic drug monitoring and clinical toxicology laboratory. I realized that every patient is different in terms of how the body metabolizes drugs and how patients very much differ in their response to medications. The ongoing paradox is that the drug development process is based on selecting a safe and effective dose for the 'average' patient. My program's goal is to promote the implementation of precision medicine and individualized precision dosing, tailoring doses to individual needs. We also work to predict how patients will respond to medications using pharmacogenetics/genomics to select the best drug and corresponding dose.

Some of our notable work includes implementing the Genetic Pharmacology Service (GPS) in 2004 and the formation of the successful startup company AssureX (now Myriad Genetics) that resulted from the GPS initiative. In recent years we have been successful in the development and implementation of electronic health records (EHR) integrated clinical decision support platforms for model-informed precision dosing. These achievements cover a variety of drugs and indications, including neonatal pain management with morphine (NeoRelief), precise hydroxyurea therapy in sickle cell anemia (HdxSim), optimizing infliximab, adalimumab and vedolizumab dosing in patients with inflammatory bowel disease (RoadMAB) and personalized reduced-intensity conditioning with melphalan in patients undergoing hematopoietic stem cell transplantation.

For additional information, please see: Personalized Medicine through Model-informed Precision Dosing: What's Here – What's Near? and Genomics Ushers in Era of Personalized Medicine.

I am honored to have received many awards and appointments throughout my career, including:

  • The American Society for Clinical Pharmacology and Therapeutics (ASCPT) Mentor Award (2020)
  • The Cincinnati Children's Research Foundation Senior Mentoring Award (2017)
  • The Cincinnati Children's Research Foundation Endowed Chair (2015)
  • The International Association Therapeutic Drug Monitoring & Clinical Toxicology Charles E. Pippenger Award (2015)
  • President, International Association for Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) (2009-2011)
  • Executive Board Member, American Board of Clinical Pharmacology, Inc. (2008-2020)
  • Fellow, American College of Clinical Pharmacology (2002-present)
  • Board certification in clinical pharmacology (2001)

I have presented my research as an invited speaker at 260 national and international conferences. I have published over 250 peer-reviewed manuscripts, 260 abstracts, 20 book chapters and invited reviews, and I am co-editor of a book on the Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics (over 38,000 chapter downloads). I’m on the editorial board of several journals, and I am an associate editor of Clinical Pharmacology & Therapeutics.

Academic Affiliation

Professor, UC Department of PediatricsAdjunct Professor of Pharmacology

Research Divisions

Clinical Pharmacology, Reproductive Sciences, Pharmacy

Blog Posts

Personalized Medicine through Model-informed Precision Dosing

Tools for Science

Personalized Medicine through Model-informed Precision Dosing

Alexander "Sander" A. Vinks, PharmD, PhD, FCP7/1/2019

Genomics Ushers in Era of Personalized Medicine

Mind Brain Behavior

Genomics Ushers in Era of Personalized Medicine

Alexander "Sander" A. Vinks, PharmD, PhD, FCP6/30/2019


Certification: American Board of Clinical Pharmacology, 2001.

PhD: Clinical Pharmacology, Leiden University, Leiden The Netherlands, 1996.

PharmD: Hospital Pharmacy, The Hague Central Hospital Pharmacy, The Hague, The Netherlands, 1986.

MS: Pharmacology, University of Toronto, Toronto Canada, 1983.

MS: Pharmacy, Leiden University, Leiden, The Netherlands, 1981.


Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia. Meier, ER; Creary, SE; Heeney, MM; Dong, M; Appiah-Kubi, AO; Nelson, SC; Niss, O; Piccone, C; Quarmyne, MO; Quinn, CT; et al. Trials. 2020; 21.

A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: A Neurofibromatosis Clinical Trials Consortium study. Ullrich, NJ; Prabhu, SP; Reddy, AT; Fisher, MJ; Packer, R; Goldman, S; Robison, NJ; Gutmann, DH; Viskochil, DH; Allen, JC; et al. Neuro-Oncology. 2020; 22:1527-1535.

Molecular Adsorbent Recirculating System Therapy with Continuous Renal Replacement Therapy Enhanced Clearance of Piperacillin in a Pediatric Patient and Led to Failure to Attain Pharmacodynamic Targets. Girdwood, ST; Arbough, T; Dong, M; Mizuno, T; Tang, P; Vinks, AA; Kaplan, J. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2020; 40:1061-1068.

Model-Informed Bayesian Estimation Improves the Prediction of Morphine Exposure in Neonates and Infants. Euteneuer, JC; Mizuno, T; Fukuda, T; Zhao, J; Setchell, KD R; Muglia, LJ; Vinks, AA. Therapeutic Drug Monitoring. 2020; 42:778-786.

Model-Informed Development of Sotalol Loading and Dose Escalation Employing an Intravenous Infusion. Somberg, JC; Vinks, AA; Dong, M; Molnar, J. Cardiology Research. 2020; 11:294-304.

MTXPK.org: A Clinical Decision Support Tool Evaluating High-Dose Methotrexate Pharmacokinetics to Inform Post-Infusion Care and Use of Glucarpidase. Taylor, ZL; Mizuno, T; Punt, NC; Baskaran, B; Sainz, AN; Shuman, W; Felicelli, N; Vinks, AA; Heldrup, J; Ramsey, LB. Clinical Pharmacology and Therapeutics. 2020; 108:635-643.

Influence of MRP3 Genetics and Hepatic Expression Ontogeny for Morphine Disposition in Neonatal and Pediatric Patients. Hahn, D; Fukuda, T; Euteneuer, JC; Mizuno, T; Vinks, AA; Sadhasivam, S; Emoto, C. Journal of Clinical Pharmacology. 2020; 60:992-998.

Hydroxyurea Exposure in Lactation: a Pharmacokinetics Study (HELPS). Ware, RE; Marahatta, A; Ware, JL; McElhinney, K; Dong, M; Vinks, AA. The Journal of Pediatrics. 2020; 222:236-239.

Population pharmacokinetic modelling of busulfan and the influence of body composition in paediatric Fanconi anaemia patients. van Hoogdalem, MW; Emoto, C; Fukuda, T; Mizuno, T; Mehta, PA; Vinks, AA. British Journal of Clinical Pharmacology. 2020; 86:933-943.

Utilizing Pediatric Physiologically Based Pharmacokinetic Models to Examine Factors That Contribute to Methadone Pharmacokinetic Variability in Neonatal Abstinence Syndrome Patients. McPhail, BT; Emoto, C; Fukuda, T; Butler, D; Wiles, JR; Akinbi, H; Vinks, AA. Journal of Clinical Pharmacology. 2020; 60:453-465.